Evaluation of six months sputum culture conversion as a surrogate endpoint in a multidrug resistant-tuberculosis trial

The emergence of multidrug resistant-tuberculosis (MDR-TB), defined as Mycobacterium tuberculosis strains with in vitro resistance to at least isoniazid and rifampicin, has necessitated evaluation and validation of appropriate surrogate endpoints for treatment response in drug trials for MDR-TB. The trial that has demonstrated efficacy of bedaquiline, a diarylquinoline that inhibits mycobacterial ATP synthase, possesses the requisite features to conduct this evaluation. Approval of bedaquiline for use in MDR-TB was based primarily on the results of the controlled C208 Stage II study (ClinicalTrials.gov number, NCT00449644) including 160 patients randomized 1:1 to receive bedaquiline or placebo for 24 weeks when added to an 18-24-month preferred five-drug background regimen. Since randomization in C208 Stage II was preserved until study end, the trial results allow for the investigation of the complex relationship between sustained durable outcome with either Week 8 or Week 24 culture conversion as putative surrogate endpoints. The relationship between Week 120 outcome with Week 8 or Week 24 culture conversion was investigated using a descriptive analysis and with a recently developed statistical methodology for surrogate endpoint evaluation using methods of causal inference. The results demonstrate that sputum culture conversion at 24 weeks is more reliable than sputum culture conversion at 8 weeks when assessing the outcome of adding one new drug to a MDR-TB regimen.status: publishe

Evaluation of six months sputum culture conversion as a surrogate endpoint in a multidrug resistant-tuberculosis trial - Fig 5

<p><b>Surrogate predictive value for A) S</b>_<b>8</b><b>and B) S</b>_<b>24</b>. The conditional probabilities of (A) ΔT given ΔS₈ or (B) ΔT given ΔS₂₄ are shown. For any individual patient, ΔT and ΔS will be -1 (Harm), 0 (Equal), and 1 (Benefit).</p

Relationship between S₈ and T for BDQ and placebo.

<p>Relationship between S₈ and T for BDQ and placebo.</p

Response rate over time in the missing = failure and multiple imputation analyses.

<p>Response rate over time in the missing = failure and multiple imputation analyses.</p

Relationship between S₂₄ and T for BDQ and placebo.

<p>Relationship between S₂₄ and T for BDQ and placebo.</p

CONSORT flow diagram for the C208 Stage II trial [19].

<p>*The modified intent-to-treat population was a subset of the intent-to-treat population that excluded nine patients (6 BDQ and 3 placebo) with Mycobacteria Growth Indicator Tube results that did not allow for primary efficacy evaluation (no evidence of culture positivity prior to first intake of blinded study drug or no results during the first 8 weeks after first intake), seven patients (3 BDQ and 4 placebo) infected with extensively drug-resistant tuberculosis, eight (4 BDQ and 4 placebo) with drug-sensitive tuberculosis, and four patients (0 BDQ and 4 placebo) for whom the multidrug-resistant tuberculosis status could not be confirmed.</p

Drop-out rate during the trial.

<p>Drop-out rate during the trial.</p

Evaluation of six months sputum culture conversion as a surrogate endpoint in a multidrug resistant-tuberculosis trial

<div><p>The emergence of multidrug resistant-tuberculosis (MDR-TB), defined as <i>Mycobacterium tuberculosis</i> strains with <i>in vitro</i> resistance to at least isoniazid and rifampicin, has necessitated evaluation and validation of appropriate surrogate endpoints for treatment response in drug trials for MDR-TB. The trial that has demonstrated efficacy of bedaquiline, a diarylquinoline that inhibits mycobacterial ATP synthase, possesses the requisite features to conduct this evaluation. Approval of bedaquiline for use in MDR-TB was based primarily on the results of the controlled C208 Stage II study (ClinicalTrials.gov number, NCT00449644) including 160 patients randomized 1:1 to receive bedaquiline or placebo for 24 weeks when added to an 18–24-month preferred five-drug background regimen. Since randomization in C208 Stage II was preserved until study end, the trial results allow for the investigation of the complex relationship between sustained durable outcome with either Week 8 or Week 24 culture conversion as putative surrogate endpoints. The relationship between Week 120 outcome with Week 8 or Week 24 culture conversion was investigated using a descriptive analysis and with a recently developed statistical methodology for surrogate endpoint evaluation using methods of causal inference.</p><p>The results demonstrate that sputum culture conversion at 24 weeks is more reliable than sputum culture conversion at 8 weeks when assessing the outcome of adding one new drug to a MDR-TB regimen.</p></div

Sensitivity, specificity, positive predictive value and negative predictive value of S₈ and S₂₄.

<p>Sensitivity, specificity, positive predictive value and negative predictive value of S₈ and S₂₄.</p

Average response rate over time in the multiple imputation analysis.

<p>Average response rate over time in the multiple imputation analysis.</p